The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
NF-kappaB: Two Sides of the Same Coin
Open accessAbstract
Nuclear Factor-kappa B (NF-κB) is a transcription factor family that regulates a large number of genes that are involved in important physiological processes, including survival, inflammation, and immune responses. More recently, constitutive expression of NF-κB has been associated with several types of cancer. In addition, microorganisms, such as viruses and bacteria, cooperate in the activation of NF-κB in tumors, confirming the multifactorial role of this transcription factor as a cancer driver. Recent reports have shown that the NF-κB signaling pathway should receive attention for the development of therapies. In addition to the direct effects of NF-κB in cancer cells, it might also impact immune cells that can both promote or prevent tumor development. Currently, with the rise of cancer immunotherapy, the link among immune cells, inflammation, and cancer is a major focus, and NF-κB could be an important regulator for the success of these therapies. This review discusses the contrasting roles of NF-κB as a regulator of pro- and antitumor processes and its potential as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“This idea was reinforced by Dvorak [66], who stated that “cancers are wounds that do not heal” (Figure 2 represents a simplified scheme of the tumor immune response).”
ResultNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 7×
“However, as previously discussed, NF-κB plays also an important role in Tregs and myeloid-derived suppressor cell functions; thus, the context, the type of infiltrating immune cells in the tumor, and the milieu are crucial for the role of NF-κB in the antitumor immunity (as simplified in Figure 3).”
BackgroundInfluentialBiomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · cited 1×
“During this biological process, transcription factors, such as SNAIL, SLUG, ZEB1, SIP1, and TWIST1, repress adhesion molecules (E-cadherin, claudins, and occludins) and stimulate markers of the mesenchymal phenotype (N-cadherin, imentin, and ibronectin) [133,134].”
Background“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792 · cited 6×
“Thus, NF-κB expression in the context of different signals afforded by ovarian cancer [169] or melanoma cells [172] can drive the expression of different genes.”
BackgroundInfluentialInhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · cited 1×
“Interestingly, anergic T CD8+ cells, which are present in different cancers and are usually associated with impaired antitumor immunity [190], have ablated NF-κB activation [140].”
BackgroundTumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560 · cited 1×
“In the same way, different proinflammatory cytokines, like IL-6 and TNF-α, are described as tumor promoters and are related to poor prognosis [206].”
BackgroundGuiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Das, J., Chen, C.-H., Yang, L., Cohn, L., Ray, P., & Ray, A. (2001) · Nature Immunology · doi:10.1038/83158 · Cited by 518
NF‐κB: roles and regulation in different CD 4+ T‐cell subsets
Oh, H., & Ghosh, S. (2013) · Immunological Reviews · doi:10.1111/imr.12033 · Cited by 408 · cited 2×
“Functions: Supports the activity of different T CD4+ cell sub-types, such as T helper 1 (Th1) and T regulatory cells (Tregs) [43].”
BackgroundIL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322 · cited 1×
“In this context, IL-10, which was categorized as a regulatory and anti-inflammatory cytokine, is now being described as an important mediator of antitumor immunity [205].”
BackgroundNF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells
Pires, B. R. B., Mencalha, A. L., Ferreira, G. M., de Souza, W. F., Morgado-Díaz, J. A., Maia, A. M., Corrêa, S., & Abdelhay, E. S. F. W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169622 · Cited by 296
Self-citationKorniluk, A., Koper, O., Kemona, H., & Dymicka-Piekarska, V. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-016-1464-0 · Cited by 282
Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278
Regulation of NF-κB by ubiquitination
Chen, J., & Chen, Z. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.005 · Cited by 258
Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
Ribeiro, S. T., Ribot, J. C., & Silva-Santos, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00015 · Cited by 116
Cited by
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Wang, L., & He, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967193 · Cited by 324
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
Neufeldt, C. J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.-Y., Plociennikowska, A., Heigwer, F., Prasad, V., Joecks, S., Burkart, S. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02983-5 · Cited by 272
Xu, P., Zhang, X., Liu, Q., Xie, Y., Shi, X., Chen, J., Li, Y., Guo, H., Sun, R., Hong, Y., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1777-9 · Cited by 270
Metadata
- Authors
- Pires, B., Silva, R., Ferreira, G., & Abdelhay, E.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2018-01-09
- Volume
- 9
- Issue
- 1
- Pages
- 24
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2782630985
- Cited by
- 237
- References
- 27
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.